Welcome to our dedicated page for Axon Enterprise SEC filings (Ticker: AXON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Axon Enterprise, Inc. filings document operating results and corporate actions for a public safety technology company with Software & Services and Connected Devices activities. Form 8-K reports include shareholder letters on financial results and outlooks, product demand across TASER devices, Axon Body cameras, Axon Evidence, AI products, counter-drone offerings and real-time operations, as well as material-event disclosures tied to capital structure.
Proxy materials cover board composition, shareholder meeting matters, executive compensation and equity awards. Other 8-K and 8-K/A filings record director election updates and the redemption and settlement of 0.50% convertible senior notes due 2027, including the disclosure that no convertible notes remained outstanding after the redemptions and conversions.
AXON ENTERPRISE, INC. Chief Product & Technology Officer Jeffrey C. Kunins reported a routine tax-related share withholding tied to vesting of performance-based restricted stock units. On June 1, 2026, 8,113.183 shares of common stock at $476.88 per share were disposed of to settle his tax liability from the vesting of the third tranche of RSUs granted under the Axon Enterprise, Inc. 2024 eXponential Stock Plan.
Following this tax-withholding disposition, Kunins directly held 59,696.817 shares of Axon common stock. Separately, he indirectly owned 86,268 shares through an LLC of which he is the sole member. The Form 4 does not show any open-market purchases or sales, only the tax withholding and updated holdings.
AXON ENTERPRISE, INC. COO & CFO Brittany Bagley reported an open-market sale of 5,969 shares of common stock on June 2, 2026 at $485.00 per share. After this transaction, she directly owned 77,084.479 shares of Axon common stock.
On June 1, 2026, 16,181.521 shares were disposed of at $476.88 per share to cover her tax liability from the vesting of the third tranche of restricted stock units granted under Axon’s 2024 eXponential Stock Plan, which is a tax-withholding event rather than an open-market sale.
Axon Enterprise president Joshua Isner reported a tax-withholding disposition of common stock tied to vesting restricted stock units. On this event, 32,796.371 shares of common stock were withheld at $476.8800 per share to settle his tax liability from the vesting of the third tranche of RSUs.
These RSUs were granted under the Axon Enterprise, Inc. 2024 eXponential Stock Plan, after performance conditions were certified by the company’s Compensation Committee on November 13, 2025. Following the tax withholding, Isner directly holds 182,124.629 shares of Axon common stock. This disposition reflects tax settlement and is not an open-market trade.
AXON ENTERPRISE, INC. executive Elizabeth Reid Coughlin, the company’s Chief Human Officer, reported two tax-withholding dispositions of common stock tied to restricted stock unit vesting. A total of 3,401.209 shares were withheld to cover her tax liabilities upon vesting, including performance-based awards under Axon’s 2024 eXponential Stock Plan. These were not open-market sales, but shares retained by the issuer for taxes. Following these dispositions, she directly holds 38,499.346 shares of Axon common stock.
AXON ENTERPRISE, INC. chief revenue officer Cameron Brooks reported a routine share disposition tied to taxes rather than a market trade. On June 1, 2026, 743.757 shares of common stock were withheld at $448.72 per share to cover tax liability from vesting restricted stock units. Following this tax-withholding event, Brooks directly holds 50,951.933 shares of Axon common stock.
Axon Enterprise Chief Legal Officer Isaiah Fields reported routine share dispositions related to tax withholding. On June 1, 2026, a total of 5,257.268 shares of common stock were disposed of at prices of $476.88 and $448.72 per share to settle tax liabilities from the vesting of restricted stock units, including awards under the Axon Enterprise, Inc. 2024 eXponential Stock Plan.
AXON ENTERPRISE, INC. director Jeri Williams reported a mix of stock award and sales. On May 29, 2026, she received 611 time-vested restricted stock units under Axon’s Amended and Restated 2022 Stock Incentive Plan, scheduled to vest in full on the earlier of the one-year anniversary of the grant date and the company’s 2027 Annual Meeting of Shareholders.
On June 1, 2026, she completed two open-market sales totaling 629 shares of common stock: 223 shares at $455.45 per share and 406 shares at a weighted average price of $477.4333 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025. Following these transactions, she directly holds 1,141 shares of Axon common stock.
AXON ENTERPRISE, INC. director Caitlin Elizabeth Kalinowski reported mixed equity activity. On June 1, 2026, she completed a series of open-market sales totaling 564 shares of Axon common stock at prices including $484.11 and $473.32 per share, leaving her with 3,632 shares held directly. Earlier, on May 29, 2026, she received a grant of 611 time-vested restricted stock units under Axon’s Amended and Restated 2022 Stock Incentive Plan, scheduled to vest in full on the earlier of the one-year anniversary of the grant date and the company’s 2027 annual meeting of shareholders.
AXON filing: a Form 144 notice reports a proposed sale of 5,969 shares of Common Stock tied to restricted stock vesting under a registered plan. The filing names Brittany Bagley as a holder and shows prior sales of 4,266 shares on 03/02/2026 with a reported value of $2,358,679.51.
SMITH GRAHAM reported acquisition or exercise transactions in this Form 4 filing.
AXON ENTERPRISE, INC. director Graham Smith received an equity award of 611 shares of Common Stock as a grant under the company’s stock incentive plan. This award is in the form of time-vested restricted stock units that vest in full on the earlier of the one-year anniversary of the grant date or the company’s 2027 Annual Meeting of Shareholders. Following this grant, Smith directly holds 3,629 shares of Axon common stock. The transaction reflects routine equity compensation rather than an open-market purchase or sale.